On November 10th, the 24th session of Shanghai International Bio-technology and Medicine Forum (BIO-FORUM), the China Bio-technology and Medicine Innovation Forum and the 2022 China Biological Medicine Science and Technology Innovation Value Award Ceremony were held in Shanghai. The forum focused on the theme of "Break-through and Integration: Scientific and Technological Innovation Drives a High-quality Development of Bio-medicine Industry". It discussed the cutting-edge technologies of biotechnology and medical industry, investment directions, and insights into the future development of the industry. Laviana Pharma was invited to join the Forum.
The forum consisted of 9 series of projects, including small molecule innovative drugs, antibody drugs, innovative therapies, biotechnology, medical devices, CXO, biotechnology industrial park, securities brokerages & investment banks and financial service institutions. Based on the potential judgmental criteria of Huayi Research Institute over the years, combined with the process of questionnaire survey, interview, date summary and data verification, the evaluation team will conduct standardized processing and comprehensive evaluation on the annual data and public information of biomedical enterprises in 2021, so as to select a number of enterprises with innovative value in that year and form an objective third-party evaluation list in the industry.
The screening process lasted for half a year from the soliciting and selection to the final release. More than 30,000 enterprises and institutions were selected one by one through independent application, recommendation from institution, big data screening and special research. It would guide biomedical innovation and provide future development direction based on all the data collected. Laviana Pharma won the award of "Top 10 Most Growing CXO Companies" with its outstanding performance in innovative research and development (R&D), as well as commercialization and enterprise growth.
Over the years, through innovative technology empowerment and key location layout, Laviana Pharma will constantly have further investment in R&D and production. Now, Laviana Pharma is growing by nearly 60% compared to 2020. The number of R&D staff has increased to more than 200, with 30% of professional staff with master's degrees or above. In addition, Laviana Pharma continues to invest in the enhancement of R&D and production capacity, accelerating the construction of the GMP production base in Cangzhou and launching the production base project in Anhui to further improve the comprehensive service capacity. Due to its investment in R&D and production, Laviana Pharma maintains its growth and vitality in the competitive environment, and has developed into an award-winning player widely known and praised by industry insiders.
Following the corporate mission of "changing the world with art of chemistry", Laviana Pharma actively explores and extends services to the downstream industry value chain. By building a leading CDMO company to accelerate global pharmaceutical innovation, we provide more one-stop comprehensive services for domestic and foreign innovative pharmaceutical companies.